All News
What Happened to Kawasaki Disease During COVID-19?
During the COVID-19 pandemic, a new COVID-related syndrome in children, the "Multisystem inflammatory syndrome in children" (MIS), was described as being similar to but distinctly different than childhood Kawasaki's disease (KD). A new epidemiologic report shows that while MIS-C cases rose, KD cases fell and remained low during the period of masking and school closure.
Read Article
Two Week Twitter (6.17.2022)
Dr. Jack Cush does a 2-week review of RheumNow Tweets on news and journal citations worth noting, along with some opinions on Telehealth, manpower, monkeypox and the price of drugs.
Read Article
PsA UPLIFT survey: do rheumatologists and patients agree on treatment goals?
POS0309 at EULAR 2022 highlighted both similarities and differences between our patients and ourselves when it comes to PsA disease and treatment strategies.
Read Article
Although Rheumatology currently ranks 2nd or 3rd in specialty use of telemedicine - the vast majority of rheums have given up on telehealth (<15%) https://t.co/8cjMjzIU0a
Dr. John Cush RheumNow ( View Tweet)
Jakne (acne) with upadacitinib: review of 857 Psoriasis pts on UPA by wk 16 9.8-15.2% c/o mild/moderate acne; only 2 D/C for acne. Higher rates seen among younger, female, non-White patients. (This rare in RA!) https://t.co/cN6NU7e5sb https://t.co/JAMYS8EIwN
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA approved Abbvies risakizumab-rzaa (Skyrizi) as the 1st interleukin-23 inhibitor for use in adults with moderately to severely active Crohn's disease (600 mg IV at wk 0, 4, 8, &q8wk @ 360 mg SC). Approval based on ADVANCE, MOTIVATE & FORTIFY RCTs https://t.co/Y6FVcjHGr2 https://t.co/eTYedqiScE
Links:
Dr. John Cush RheumNow ( View Tweet)
Long term risk of Herpes zoster in 1157 pts on tofacitinib for ulcerative colitis was Tofa 3.62 vs PBO 1.98/100PY during induction; during maintenace was Tofa 5mg 2.05 vs 10 mg 6.64 vs PBO 0.97/100PY. Higher risk w/ age, low wt, prior TNFi, N.American https://t.co/E3PGvejAUF https://t.co/k8PIT2o5KI
Links:
Dr. John Cush RheumNow ( View Tweet)
31 systemic JIA pts: w/ systemic sxs (n=8), chronic arthritis (7), remission on meds (10) & remission off meds (6). High IL-18 levels & impaired IL-18 signaling in NK cells correlated with systemic Dz activity. High IL-18 impairs NK phosphorylation https://t.co/hKTRdhuQVN https://t.co/qM5jYB3yi5
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 1778 #SLE pts, of whom 121 had refractory thrombocytopenia (TP)(Plt <50K, unresp. to pred), Risk factors included pregnancy, Autoimmune hemolytic anemia, decreased C3, severity of TP and elevated ACL-IgG. https://t.co/ZNqQfUoYUq https://t.co/eQNcKcc9Uz
Links:
Dr. John Cush RheumNow ( View Tweet)
New podcast up, titled 'Two Week Twitter'
Dr. Jack Cush does a 2-week review of RheumNow Tweets on news and journal citations worth noting, along with some opinions on Telehealth, manpower, monkeypox and the price of drugs.'
https://t.co/tfBeKA0Arz https://t.co/CXYmEKNqDE
Links:
Dr. John Cush RheumNow ( View Tweet)
OA Initiative Study of 1212 knee OA pts (age 63 yrs), 73% walked for exercise. Walkers had signif. less New frequent knee pain (OR 0.6) & medial joint space narrowing (OR 0.8). Walking for exercise should be encouraged in knee OA pts. https://t.co/wCKjxwJ9EG
Links:
Dr. John Cush RheumNow ( View Tweet)
Yesterday the FDA approved baricitinib (Olumiant) as the first systemic treatment for Alopecia Areata. Approval based on 2 DBRPCT Trial AA-1, AA-2) - 32% & 35% of pts on Bari 4 mg regrew scalp hair coverage by wk 36. https://t.co/QkB97B6Qjz https://t.co/5HmtBnpGqE
Links:
Dr. John Cush RheumNow ( View Tweet)
We've got a new download available titled "Travel Tips for Arthritis Travelers"
Head over to RheumNow and download today.
https://t.co/COamlQvlIs https://t.co/wxGBTtuv2f
Links:
Dr. John Cush RheumNow ( View Tweet)
JAKi not yet safe in pregnancy - theyre fetotoxic at high doses (animals). JAKi do cross placenta. ACR Guidelines: no position due to no data. 47 tofa Rheum & 15 UC maternal exposures - no signif probs. Paternal use of JAKi is ok.
https://t.co/PoIheshd2n https://t.co/gjTN2Uz4IP https://t.co/OAfLRvSFBs
Dr. John Cush RheumNow ( View Tweet)
#EULAR2022 has concluded but you can find all our coverage here https://t.co/s62OVJPQ86 https://t.co/QAvPQYCABj
Links:
Dr. John Cush RheumNow ( View Tweet)
From OP Internationa: The Clinician’s Guide to prevention & Rx of OP -concise recommendations regarding prevention, risk assessment, diagnosis, and treatment of osteoporosis in postmenopausal women & men >50 yrs of age https://t.co/z3ZJ3lIplG
Links:
Dr. John Cush RheumNow ( View Tweet)
Learn more about the IL-23 pathway and our clinical research in #psoriaticdisease here: https://t.co/jDuYR9fZ10 Sponsored by Janssen @JanssenUS@JanssenUS https://t.co/kjekl1teNX
Links:
Dr. John Cush RheumNow ( View Tweet)
JAK/STAT pathway in pyoderma gangrenosum: a new therapeutic highway?
Pyoderma gangrenosum (PG) is rare, but often associated with different forms of arthritis, in particular rheumatoid arthritis and inflammatory bowel diseases.
https://t.co/QHNHsyWNbx https://t.co/Arlq03uiLE
Links:
Dr. John Cush RheumNow ( View Tweet)
Flares Not Increased Following RZV Injections
Insurance claims analysis has shown that the use of the RZV for prevention of HZ was highly used in patients with IMIDs and was safe, as higher rates of arthritis flares were not evident.
https://t.co/E27oIBlEDb https://t.co/VbtDnmRYzO
Links:
Dr. John Cush RheumNow ( View Tweet)
Watch: Dr. Lucy Carter on RNA-Seq analysis to determine who's at risk for SLE
Dr. Yusof interviews Dr. Lucy Carter ( @LucyCarter6), winner of the #EULAR2022 Best Abstract Award for her work on ANA positivity in those at-risk for progression to #SLE.
https://t.co/BdPnZRgwX4 https://t.co/g8xWWFthVC
Links:
Dr. John Cush RheumNow ( View Tweet)
